Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) major shareholder Coastlands Capital Lp bought 20,000 shares of the business’s stock in a transaction on Tuesday, November 17th. The stock was bought at an average price of $5.75 per share, with a total value of $115,000.00. Following the transaction, the insider owned 515,510 shares in the company, valued at approximately $2,964,182.50. This represents a 4.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Coastlands Capital Lp also recently made the following trade(s):
- On Monday, November 16th, Coastlands Capital Lp bought 33,094 shares of Bolt Biotherapeutics stock. The shares were bought at an average cost of $5.89 per share, with a total value of $194,923.66.
- On Monday, November 9th, Coastlands Capital Lp purchased 50,000 shares of Bolt Biotherapeutics stock. The shares were bought at an average price of $6.38 per share, for a total transaction of $319,000.00.
Bolt Biotherapeutics Trading Down 2.6%
Bolt Biotherapeutics stock opened at $5.65 on Wednesday. Bolt Biotherapeutics, Inc. has a 12 month low of $3.10 and a 12 month high of $7.78. The company has a quick ratio of 2.61, a current ratio of 2.05 and a debt-to-equity ratio of 2.06. The stock has a market cap of $14.75 million, a P/E ratio of -0.38 and a beta of 0.85. The company’s fifty day simple moving average is $4.70 and its 200-day simple moving average is $4.51.
Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($2.25) EPS for the quarter, beating the consensus estimate of ($3.68) by $1.43. Bolt Biotherapeutics had a negative return on equity of 154.11% and a negative net margin of 611.47%. The business had revenue of $0.45 million during the quarter, compared to analysts’ expectations of $0.45 million. As a group, sell-side analysts forecast that Bolt Biotherapeutics, Inc. will post -11.10 EPS for the current fiscal year.
Institutional Investors Weigh In On Bolt Biotherapeutics
A hedge fund recently raised its position in Bolt Biotherapeutics stock. Renaissance Technologies LLC increased its holdings in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) by 40.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 77,225 shares of the company’s stock after purchasing an additional 22,200 shares during the period. Renaissance Technologies LLC owned approximately 4.02% of Bolt Biotherapeutics worth $312,000 at the end of the most recent reporting period. 86.70% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $14.50.
Get Our Latest Report on Bolt Biotherapeutics
About Bolt Biotherapeutics
Bolt Biotherapeutics is a clinical-stage biotechnology company based in Redwood City, California. It develops immunotherapies designed to direct the body’s immune system against cancer. The company’s Boltbody platform is designed to pair tumor-targeting antibodies with immune-stimulating components. Its pipeline has included BDC-3042, an investigational antibody intended to activate macrophages, immune cells that can help recognize and attack tumors. Bolt has also developed BDC-1001, an investigational HER2-targeting immune-stimulating antibody conjugate.
Recommended Stories
- Five stocks we like better than Bolt Biotherapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
